BiotechTube

CPK850

Phase 1/2Active
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Retinitis Pigmentosa

Conditions

Retinitis Pigmentosa

Trial Timeline

Aug 22, 2018 → May 11, 2026

NCT ID
NCT03374657

About CPK850

CPK850 is a phase 1/2 stage product being developed by Novartis for Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT03374657. Target conditions include Retinitis Pigmentosa.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03374657Phase 1/2Active

Competing Products

20 competing products in Retinitis Pigmentosa

See all competitors
ProductCompanyStageHype Score
DSP-3077 Retinal Sheet Cohort 1 + DSP-3077 Retinal Sheet Cohort 2 + DSP-3077 Retinal Sheet Cohort 3Sumitomo PharmaPhase 1/2
41
AGN-151597AbbViePhase 1/2
41
Valganciclovir + GanciclovirRochePhase 3
77
ValganciclovirRochePre-clinical
23
Foscarnet sodium + GanciclovirRochePhase 1
33
GanciclovirRochePhase 1
33
GanciclovirRochePre-clinical
23
GanciclovirRochePhase 2
52
GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
Zidovudine + Sargramostim + GanciclovirRochePre-clinical
23
Zidovudine + GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
Interferon beta-1b + GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
GanciclovirRochePre-clinical
23
GanciclovirRochePhase 3
77
ValganciclovirRochePhase 3
77
Cidofovir + ProbenecidGilead SciencesPre-clinical
22
Cidofovir + ProbenecidGilead SciencesPre-clinical
22

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85